The significant revenue decline and cash burn to $3.1 million raise concerns about funding for the planned Phase 3 trial. Traders should monitor for potential dilutive financing needs despite the positive regulatory progress on GEO-MVA.
Price Chart
Executive Summary
GeoVax Labs reported its 2025 year-end financial results, highlighting progress on its GEO-MVA mpox vaccine program, including regulatory alignment with the EMA and manufacturing readiness for a pivotal Phase 3 trial expected in the second half of 2026. The company reported a net loss of $21.5 million on $2.5 million in government contract revenue.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $21.5 million, or $22.40 per share, compared to a $25.0 million loss in 2024
- Revenue was $2.5 million from BARDA/RRPV Project NextGen award, down from $4.0 million in 2024
- R&D expenses decreased to $18.1 million from $23.7 million in 2024 due to termination of BARDA contract
- G&A expenses increased to $6.0 million from $5.4 million in 2024
- Cash position declined to $3.1 million as of December 31, 2025, from $5.5 million at year-end 2024
- Company plans to initiate pivotal Phase 3 trial for GEO-MVA mpox vaccine in second half of 2026
Financial Impact
Revenue decreased 37.5% year-over-year from $4.0 million to $2.5 million; net loss per share increased from $120.46 to $22.40 (due to share count increase)
Risk Factors
- Cash position of $3.1 million may be insufficient to fund planned Phase 3 trial without additional financing
- Dependence on government contracts creates revenue volatility
- Dilutive equity offerings likely needed to fund development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-012435 |
| Document: govx20260415_8k.htm | 0001437749-26-012435 |
| Document: 0001437749-26-012435-index-headers.html | 0001437749-26-012435 |
| Document: 0001437749-26-012435-index.html | 0001437749-26-012435 |
| Document: 0001437749-26-012435.txt | 0001437749-26-012435 |
| 8-K Data (Synthetic) | 0001437749-26-012435 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.2032 | awaiting T+60 | — | $0.1940 (+4.53%) |
Sep 24, 2026 4w ago | EFFECT | $0.3603 | awaiting T+60 | — | $0.1940 (+46.16%) |
Jun 4, 2026 20w ago | EFFECT | $1.79 $0.7210 | ▲ +59.72% | ▲ +61.60% | $0.1940 (+89.16%) |
May 26, 2026 22w ago | S-1 | $3.49 $0.5947 | ▼ −82.96% | ▼ −85.68% | $0.1940 (−94.44%) |
May 19, 2026 23w ago | 8-K | $2.23 $0.7180 | ▲ +67.80% | ▲ +72.81% | $0.1940 (+91.30%) |
May 14, 2026 23w ago | 8-K | $1.23 $0.7700 | ▲ +37.40% | ▲ +41.91% | $0.1940 (+84.23%) |
May 7, 2026 24w ago | 8-K | $1.67 $0.7620 | ▲ +54.37% | ▲ +59.21% | $0.1940 (+88.38%) |
Apr 22, 2026 26w ago | EFFECT | $1.17 $0.9742 | ▼ −16.73% | ▼ −21.51% | $0.1940 (−83.42%) |
Apr 20, 2026 27w ago | EFFECT | $1.17 $1.01 | ▲ +13.68% | ▲ +20.45% | $0.1940 (+83.42%) |
Apr 15, 2026 27w ago | 8-K | $1.23 $1.11 | ▲ +9.76% | ▲ +16.80% | $0.1940 (+84.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers